Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

11
5 Low-Cost Biotech Stocks With High Levels of Growth

5h investorplace
Biotech stocks have a reputation for risk. But not all biotechs are small-cap stocks without any products on the market. And not all biotech stocks act as glorified lottery tickets.
ABT REGN JAZZ CELG SUPN ABT SNY

3
FDA Action Alert: Mallinckrodt, Kala Pharma, Merck, Eisai and More

15h biospace
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look.
REGN KALA AGIO

3
Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose

2018-08-20 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA has approved a supplemental Biologics License Application (sBLA) for its flagship ophthalmology drug, Eylea injection in patients with wet age-related macular degeneration (wet AMD).
REGN TXN NVS SNY

1
Biotech Analysis Central Pharma News: Regeneron's Reversal Of Fortune, Bristol-Myers Squibb's FDA Win, Novo Nordisk's Acquisition

2018-08-20 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
REGN NVS

40
Your Daily Pharma Scoop: Fasinumab Positive, Teva And Sun Gets FDA Approval

2018-08-19 seekingalpha
Discussion: Development partners Regeneron Pharmaceuticals (REGN) and Teva Pharmaceutical Industries (TEVA) reported topline results of a Phase 3 clinical trial. The trial was evaluating fasinumab in patients with chronic pain from osteoarthritis of the knee or hip. This is a smaller sub-set involving 3565 patients out of the larger planned trial that involves upto 7000 patients. The main study has a time frame of baseline to 72nd week an during this period the incidence of severe destructive arthropathy (‘DA) will be the primary safety endpoint.
REGN INO CORV TROV TEVA TEVVF BHVN EDIT TEVJF MRK WVE IOVA BMY

21
Your Daily Pharma Scoop: Opdivo Is Approved On SCLC, Mateon Trial On Hold, Tandem Product Launch

2018-08-19 seekingalpha - 1
Discussion: Bristol-Myers Squibb's (BMY) OPDIVO (nivolumab) is now FDA approved for patients with metastatic small cell lung cancer (‘SCLC) that has progressed after platinum-based chemo and at least one prior line of therapy. This is the first and till date only FDA-approved Immuno-Oncology treatment option for this patient category. Also because this is the first successful checkpoint inhibitor to be approved for these indications, the researchers consider approval of nivolumab to be “particularly exciting.
ATRS REGN VRTX TEVJF TEVA TEVVF TNDM

16
Why Teva and Regeneron Are Popping

2018-08-16 247wallst
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
REGN TEVJF TEVA TEVVF

0
What the FDA Has to Say About Regeneron’s Eylea

2018-08-15 247wallst
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing some difficulty after it received an update from the U.S. Food and Drug Administration (FDA).
REGN

3
Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

2018-08-14 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License Application (sBLA) for Eylea injection due to ongoing labeling discussions.
REGN NVS SNY

4
Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential

2018-08-14 zacks
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is Regeneron Pharmaceuticals, Inc.
HD REGN ESES CSX TERP

1
Regeneron's Pain Is Novartis' Gain

2018-08-14 seekingalpha
Novartis gains advantage as Regeneron runs into labeling issue for the sBLA of its 12-week injection dosing for EYLEA.
REGN NVS CRL

13
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

2018-08-09 zacks
Sarepta Therapeutics, Inc. (SRPT - Free Report) incurred a loss of 43 cents per share in the second quarter of 2018, narrower than the year-ago loss of 48 cents and the Zacks Consensus Estimate of a loss of 47 cents.
SGEN VRTX REGN SRPT UCTI UCTT

8
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

2018-08-08 zacks
The key headlines in the biotech sector this week include Regeneron Pharmaceuticals’ (REGN - Free Report) strong Q2 results and its $100 million investment in bluebird bio (BLUE - Free Report) . Meanwhile, among regular pipeline and regulatory updates, Gilead (GILD - Free Report) is making further inroads into China with its HIV franchise.
VRTX REGN ELY ICFI BLUE BLUE ONCE

22
AbbVie's Outlook Remains Blurred

2018-08-07 seekingalpha
AbbVie remains over-reliant on sales of Humira to drive top-line sales - a major red flag as the worldwide patent protection is about to lapse.
REGN GILD JNJ ABBV ABBV

0
A Roundup of Major Q2 Reports: Biogen, AstraZeneca, Pfizer and More

2018-08-07 biospace
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
REGN

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 75886F107